文献速递产科母胎医学

软件引导的胰岛素给药改善糖尿病产妇产时血糖管理

Software-guided insulin dosing improves intrapartum glycemic management in women with diabetes mellitus.
PubMed 文献 · Am J Obstet Gynecol · 2018-05-08

该回顾性队列研究比较了标准胰岛素剂量表与GlucoStabilizer软件引导的静脉胰岛素给药在需要产时胰岛素输注的糖尿病产妇中的效果。软件组达到目标血糖范围(70-100 mg/dL;3.9-5.5 mmol/L)的比例为81.8%,显著高于标准组的9.1%(P<.001),且未增加产妇低血糖(0% vs 4.3%;P=.99)。

要点

  • 软件引导组产时达到目标血糖(70-100 mg/dL)的比例为81.8%,标准组为9.1%(P<.001)。
  • 软件组产妇低血糖发生率为0%,标准组为4.3%(P=.99),无显著差异。
  • 软件组平均毛细血管血糖为102.9±5.9 mg/dL,低于标准组的121.7±5.9 mg/dL(P=.02)。

核心结论

  • 使用软件引导的静脉胰岛素给药可改善产时血糖管理,且不增加低血糖,适用于需要胰岛素输注的孕前和妊娠期糖尿病产妇。

研究设计与样本

  • 回顾性队列研究,比较2012年1月至2017年12月期间需要产时胰岛素输注的糖尿病产妇,按标准胰岛素剂量表(22例)与GlucoStabilizer软件(11例)分组,软件于2016年5月实施并取代标准剂量表。

主要发现

  • 软件组产时达到目标血糖范围(70-100 mg/dL;3.9-5.5 mmol/L)的比例为81.8%,标准组为9.1%(P<.001)。
  • 软件组产妇低血糖发生率为0%,标准组为4.3%(P=.99)。
  • 软件组平均毛细血管血糖为102.9±5.9 mg/dL(5.7±0.33 mmol/L),标准组为121.7±5.9 mg/dL(6.8±0.33 mmol/L)(P=.02)。
  • 输注开始前两组平均毛细血管血糖均高于目标范围:软件组122.6±8.8 mg/dL(6.7±0.49 mmol/L),标准组131.9±10.1 mg/dL(7.3±0.56 mmol/L)(P=not significant)。
  • 两组基线产妇特征及新生儿结局无显著差异。

临床怎么用

  • 作者认为,在产科使用软件引导的静脉胰岛素给药可改善产时血糖管理且不增加低血糖。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: During labor, maintenance of maternal euglycemia is critical to decrease the risk of neonatal hypoglycemia and associated morbidities. When continuous intravenous insulin infusion is needed, standardized insulin dosing charts have been used for titration of insulin to maintain glucose in target range. The GlucoStabilizer software program (Indiana University Health Inc, Indianapolis, IN) is a software-guided insulin dosing system that calculates the dose of intravenous insulin that is needed based on metabolic parameters, target glucose concentration, and an individual's response to insulin. Although this tool has been validated and shown to reduce both hypoglycemia and errors in critical care settings, the utility of this software has not been examined in obstetrics. OBJECTIVE: The purpose of this study was to determine whether the use of intravenous insulin dosing software in women with pregestational or gestational diabetes mellitus that requires intrapartum insulin infusion can improve the rate of glucose concentration in target range (70-100 mg/dL; 3.9-5.5 mmol/L) at the time delivery. STUDY DESIGN: We performed a retrospective cohort study comparing laboring patients with diabetes mellitus that required insulin infusion who were dosed by standard insulin dosing chart vs the GlucoStabilizer software program from January 2012 to December 2017. The GlucoStabilizer software program, which was implemented in May 2016, replaced the standard intravenous insulin dosing chart. Inclusion criteria were women with pregestational or gestational diabetes mellitus who were treated with an intravenous insulin infusion intrapartum for at least 2 hours. Maternal characteristics, glucose values in labor, and neonatal outcomes were extracted from delivery and neonatal records. The primary outcome was the percentage of women who achieved the target glucose range (defined as a blood glucose between 70-100 mg/dL; 3.9-5.5 mmol/L) before delivery. Parametric and nonparametric statistics were used to compare both groups; a probability value of <.05 was considered statistically significant. RESULTS: We identified 22 patients who were dosed by a standard insulin dosing chart and 11 patients who were dosed by the GlucoStabilizer software program during intrapartum management. The GlucoStabilizer software program was superior in achieving glucose values in target range at delivery (81.8% vs 9.1%; P<.001) compared with standard insulin dosing without increasing maternal hypoglycemia (0% vs 4.3%; P=.99). Patients whose insulin dosing was managed by the GlucoStabilizer software program also had lower mean capillary blood glucose values compared with the standard insulin infusion (102.9±5.9 mg/dL [5.7±0.33 mmol/L] vs 121.7±5.9 mg/dL [6.8±0.33 mmol/L]; P=.02). Before the initiation of the infusion, both groups demonstrated mean capillary blood glucose values outside of target range (122.6±8.8 mg/dL [6.7±0.49 mmol/L] for the GlucoStabilizer software program vs 131.9±10.1 mg/dL [7.3±0.56 mmol/L] for standard insulin treatment group; P=not significant). There were no significant differences in baseline maternal characteristics between the groups or neonatal outcomes. CONCLUSION: This study is the first to demonstrate that the use of software-guided intravenous insulin dosing in obstetrics can improve intrapartum glycemic management without increasing hypoglycemia in women with both pregestational and gestational diabetes mellitus that is treated with an insulin infusion.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Dinglas C, Muscat J, Adams T, et al. Software-guided insulin dosing improves intrapartum glycemic management in women with diabetes mellitus. Am J Obstet Gynecol. 2018. PMID: 29750952. doi:10.1016/j.ajog.2018.05.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。